About
Therapies for immunological diseases and cancer
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyBiotech
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
247
By Phase
PHASE2/PHASE3: 1PHASE1: 1
By Status
RECRUITING: 1COMPLETED: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT05416307Lead Sponsor
Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
PHASE2/PHASE3Recruiting
156 participants
Started: May 19, 2022 · Completed: Jun 30, 2029
NCT05556863Lead Sponsor
Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Volunteers
PHASE1Completed
91 participants
Started: Oct 18, 2021 · Completed: Nov 20, 2023
Locations (1)
Headquarters
South SF, CA, United States
Map
Loading map...